MedPath

Investigation of Vascular Relaxing Effects of Candesartan and Pioglitazone.

Not Applicable
Completed
Conditions
Healthy Subjects
Registration Number
NCT00154037
Lead Sponsor
Technische Universität Dresden
Brief Summary

The study is designed to test the hypothesis in healthy subjects that candesartan and pioglitazone provide additional vascular relaxing or modulating effects in addition to their blood-pressure and blood glucose level reducing ability, respectively.

Detailed Description

The aim of the study is to investigate the effect of oral candesartan and/ or rosiglitazone therapy on the vascular responsiveness of different vasoactive compounds (angiotensin II, insulin, histamine and glyceroltrinitrate) in healthy subjects. Pioglitazone will be given orally (4 weeks 30mg/d, titrated to 45 mg/d for another 4 weeks). Candesartan will be given orally (4 weeks 8mg/d, titrated to 16 mg/d for another 4 weeks) as treatment. Every subject will receive intravenous stimulation with phenylephrine, angiotensin II, histamine, insulin and glyceroltrinitrate before and after an 8 weeks treatment interval with study medication or placebo. In addition, pulse wave velocity will me measured non-invasively before and after treatment.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
40
Inclusion Criteria
  • Male
  • healthy
  • 18 - 40 years old
  • non-smoker
  • no additional medication
Read More
Exclusion Criteria
  • any relevant disease
  • smokers
  • elevated liver enzymes
  • body weight different from Broca Norm > 20%
  • allergies
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Vascular reactivity
Secondary Outcome Measures
NameTimeMethod
Pulse wave velocity
Changes in Angiotensin metabolites

Trial Locations

Locations (1)

Institute of Clinical Pharmacology, Medical Faculty, University of Technology

🇩🇪

Dresden, Germany

© Copyright 2025. All Rights Reserved by MedPath